Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23466485)

1.

Early-phase development of cancer prevention agents: challenges and opportunities.

Perloff M, Steele VE.

Cancer Prev Res (Phila). 2013 May;6(5):379-83. doi: 10.1158/1940-6207.CAPR-12-0463. Epub 2013 Mar 6.

2.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
3.

Rapid access to preventive intervention development program in the Division of Cancer Prevention of the U.S. National Cancer Institute: an overview.

Kapetanovic IM.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):698-700. doi: 10.1158/1055-9965.EPI-08-1007. Epub 2009 Feb 24. No abstract available.

4.

NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ Jr, Bentzen SM, Okunieff P, Coleman CN, Dicker AP.

J Natl Cancer Inst. 2013 Jan 2;105(1):11-24. doi: 10.1093/jnci/djs472. Epub 2012 Dec 10.

5.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

6.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
7.

Development of breast cancer chemopreventive drugs.

Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Doody LA, Greenwald P.

J Cell Biochem Suppl. 1993;17G:2-13. Review.

PMID:
8007699
8.

Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.

Greenwald P.

J Cell Biochem Suppl. 1996;25:29-36. Review.

PMID:
9027595
10.

Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.

Johnson KA, Ford LG, Kramer B, Greenwald P.

Acta Oncol. 1994;33(1):5-11. Review.

PMID:
8142125
11.

Approaches to the development and marketing approval of drugs that prevent cancer.

Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G, et al.

Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):1-10. Review.

12.

Do we make optimal use of the potential of cancer prevention?

Greenwald P, Dunn BK.

Recent Results Cancer Res. 2009;181:3-17. Review.

PMID:
19213552
13.

The preclinical new drug research program of the National Cancer Institute.

Driscoll JS.

Cancer Treat Rep. 1984 Jan;68(1):63-76.

PMID:
6692438
14.

Anticancer Drug Development: The Way Forward.

Connors T.

Oncologist. 1996;1(3):180-181.

15.

Chemoprevention research at the U.S. National Cancer Institute.

Greenwald P.

Mil Med. 1994 Jul;159(7):505-12. Review.

PMID:
7816223
16.

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.

Christian MC, Pluda JM, Ho PT, Arbuck SG, Murgo AJ, Sausville EA.

Semin Oncol. 1997 Apr;24(2):219-40. Review.

PMID:
9129691
17.

A National Cancer Clinical Trials Network: recommendations from the Institute of Medicine.

Nass SJ, Balogh E, Mendelsohn J.

Am J Ther. 2011 Sep;18(5):382-91. doi: 10.1097/MJT.0b013e3181ff7e23.

18.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

19.

The National Cancer Institute: cancer drug discovery and development program.

Grever MR, Schepartz SA, Chabner BA.

Semin Oncol. 1992 Dec;19(6):622-38. Review.

PMID:
1462164
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk